Skip to main content
. 2021 Mar 11;15:1111–1133. doi: 10.2147/DDDT.S292805

Table 2.

Experimental Groups, Group Size, and Administered Treatments

Name of the Group Group Sizea Administered Treatment
NC 72 Zebrafish with no xenotransplantation and no SARS-CoV-2 induction
XMC 72 Zebrafish transplanted with human alveolar epithelial A549 cells on the posterior lobe of swim bladder
DC 72 XMC injected with SARS-CoV-2 recombinant S-protein
1X-Dexa-HED 72 DC administered with 0.08 µg/kg body weight of dexamethasone through feed
0.2X-HED 72 DC administered with 6 µg/kg body weight of WiNeWsE through feed
1X-HED 72 DC administered with 28 µg/kg body weight of WiNeWsE through feed
5X-HED 72 DC administered with 142 µg/kg body weight of WiNeWsE through feed

Notes: aThere were 24 subjects/group/endpoint. There were three endpoints in this study.

Abbreviations: NC, normal control; XMC, xenotransplant model control; DC, disease control; 1X-Dexa-HED, human equivalent dose of dexamethasone; WiNeWsE, withanone enriched Withania somnifera extract; 0.2X-HED, 0.2X human equivalent dose of WiNeWsE; 1X-HED, human equivalent dose of WiNeWsE; 5X-HED, 5X human equivalent dose of WiNeWsE.